Could be a good time for launching a replacement, like the Sumatriptan VIBEX® auto injector..
Teva Pharmaceutical Industries, Ltd. (NYSE and TASE:TEVA) announced today that it will voluntarily suspend sales, marketing and distribution of ZECUITY® (sumatriptan iontophoretic transdermal system). Teva has received post-marketing reports of application site reactions described as burns and scars in patients treated with ZECUITY, and is working in full cooperation with the U. S. Food and Drug Administration (FDA) to better understand these adverse events. In addition to this voluntary suspension, Teva has initiated a pharmacy-level recall of the product.
Takeaway message: "The settlement allows Teva to commercialize its generic version of BYETTA in the U.S. beginning October 15, 2017 or earlier under certain circumstances."
Teva settles patent litigation with AstraZeneca, enters into license agreement Teva Pharmaceuticals USA (TEVA) announced that it has settled the patent litigation with AstraZeneca Pharmaceuticals LP (AZN), AstraZeneca AB and Amylin Pharmaceuticals, LLC (AMLN) relating to AstraZeneca's US Patent Nos. 6,858,576, 6,872,700, 6,956,026, 7,297,761, 6,902,744, 7,521,423, and 7,741,269 and AstraZeneca's BYETTA, and entered into a settlement and license agreement with AstraZeneca, pursuant to which AstraZeneca granted a license to Teva to manufacture and commercialize the generic version of BYETTA described in Teva's ANDA No. 205984 in the United States. The settlement allows Teva to commercialize its generic version of BYETTA in the U.S. beginning October 15, 2017 or earlier under certain circumstances. All other terms of the agreement are confidential. BYETTA is an injectable product used to treat type 2 diabetes. Teva remains committed to strengthening its presence in its generic injectable business globally. Teva continues investment in new, and higher-value generic injectable products. With approximately 370 generic medicines available, Teva has the largest portfolio of FDA-approved generic products and continues to bring new products to market for the patients who need them.
Read more at: